 H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. NASDAQ:CCXI following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on shares of ChemoCentryx, Inc. with a 28 price target. 